Amneal Pharmaceuticals, Inc. (AMRX)
Price:
14.65 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Phibro Animal Health Corporation
VALUE SCORE:
5
2nd position
Neurocrine Biosciences, Inc.
VALUE SCORE:
9
The best
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
NEWS
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
zacks.com
2026-02-23 10:41:34Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $13.80
defenseworld.net
2026-02-16 01:58:52Shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
prnewswire.com
2026-02-13 11:26:00/PRNewswire/ -- Equity-Insider.com News Commentary - The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual
Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now?
zacks.com
2026-02-05 10:40:53Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
globenewswire.com
2026-01-28 16:05:00BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index.
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
zacks.com
2026-01-28 13:11:11Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
prnewswire.com
2026-01-27 18:02:00NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE: CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE: SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions.
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
globenewswire.com
2026-01-27 08:00:00BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
zacks.com
2026-01-22 10:41:33Here is how Amneal Pharmaceuticals (AMRX) and Biohaven Ltd. (BHVN) have performed compared to their sector so far this year.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $13.80 Average PT from Brokerages
defenseworld.net
2026-01-22 01:15:04Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Grows By 28.4%
defenseworld.net
2026-01-19 05:00:51Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 6,851,192 shares, an increase of 28.4% from the December 15th total of 5,336,430 shares. Approximately 2.6% of the company's stock are sold short. Based on an
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
zacks.com
2026-01-15 10:40:34Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-13 23:36:01Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease
businesswire.com
2026-01-09 11:00:00WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to support the pre-IND development of KFRX06, KeifeRx's preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2), a gene strongly implicated in Parkinson's disease biology. Under the agreement, KeifeRx will conduc.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Analysts
defenseworld.net
2025-12-25 03:16:58Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net
2025-12-25 03:16:56Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price
No data to display
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
zacks.com
2026-02-23 10:41:34Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $13.80
defenseworld.net
2026-02-16 01:58:52Shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
prnewswire.com
2026-02-13 11:26:00/PRNewswire/ -- Equity-Insider.com News Commentary - The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual
Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now?
zacks.com
2026-02-05 10:40:53Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
globenewswire.com
2026-01-28 16:05:00BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index.
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
zacks.com
2026-01-28 13:11:11Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
prnewswire.com
2026-01-27 18:02:00NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE: CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE: SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions.
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
globenewswire.com
2026-01-27 08:00:00BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
zacks.com
2026-01-22 10:41:33Here is how Amneal Pharmaceuticals (AMRX) and Biohaven Ltd. (BHVN) have performed compared to their sector so far this year.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $13.80 Average PT from Brokerages
defenseworld.net
2026-01-22 01:15:04Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Grows By 28.4%
defenseworld.net
2026-01-19 05:00:51Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 6,851,192 shares, an increase of 28.4% from the December 15th total of 5,336,430 shares. Approximately 2.6% of the company's stock are sold short. Based on an
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
zacks.com
2026-01-15 10:40:34Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-13 23:36:01Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease
businesswire.com
2026-01-09 11:00:00WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to support the pre-IND development of KFRX06, KeifeRx's preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2), a gene strongly implicated in Parkinson's disease biology. Under the agreement, KeifeRx will conduc.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Analysts
defenseworld.net
2025-12-25 03:16:58Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net
2025-12-25 03:16:56Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price